28 Aug 2013 IVM Offers Alternative to IVF
In-Vitro Maturation, or IVM, is one of the newest technologies being utilized in the fertility field as a cost-efficient, safe alternative to In-Vitro Fertilization (IVF). Some women undergoing IVF are prone to a dangerous side effect known as ovarian hyperstimulation syndrome (OHSS), particularly common in patients with a type of hormonal imbalance called polycystic ovary syndrome (PCOS).
IVM is similar to In-Vitro Fertilization with some notable differences. The most prominent variance between the two treatments is the time at which infertile eggs are collected. As in conventional IVF, eggs are collected from the intended mother or an egg donor, but at an earlier stage in the eggs’ developmental process, so that the donor receives significantly less ovary-stimulating medications. Although the success rate with IVM is roughly similar to that of IVF, fewer eggs typically are collected via IVM, and there is a higher risk that not all eggs collected will mature sufficiently, according to the U.K.’s independent regulatory agency Human Fertilisation and Embryology Authority.
Although it is estimated that fewer than 4,000 babies have been born worldwide as a result of IVM, compared to some 5 million babies born via IVF, IVM is an evolving technology likely to become increasingly common. Dr. Jin-Ho Lim, founder of the New York-based Neway Clinic, recently reported its first three pregnancies resulting from IVM in North America.